Company Overview and News

Bursa opens lower in unsettled market

30m malaymail
KUALA LUMPUR, June 19 — Bursa Malaysia opened lower today as the mood across markets remained unsettled on concerns over a further escalation in trade tensions between the US and China.
PBLOF 1295 BSMAF 7123 1818

KLCI falls 0.37% in line with loss at regional markets

31m theedgemarkets
KUALA LUMPUR (June 19): The FBM KLCI fell 0.37% in early trade this morning in line with the retreat at most regional markets, on heightened worries over the trade spat between the world’s two largest economies.
HLFBF KLKBY 2445 PBLOF 4065 1082 5681 BATS 4162 1295 7153 3719

Bursa Malaysia ends at over two-week low

15h malaymail
KUALA LUMPUR, June 18 — Bursa Malaysia extended last week’s losses to close at its lowest level since May 31, 2017, mainly hurt by gloomy market sentiment amid weaker crude oil prices, dealers said.
PBLOF 1295 BSMAF 1818

Bursa ends morning session in the red

21h malaymail
KUALA LUMPUR, June 18 — Bursa Malaysia ended the morning session in the red on bearish sentiment, while tracking the weak performance of regional peers.
3301 PBLOF 5819 5681 1295 BSMAF 1818

Bursa remains lower at mid-morning

23h malaymail
KUALA LUMPUR, June 18 — Bursa Malaysia extended losses to mid-morning today, hampered by continued selling pressure in heavyweights, led by Axiata and Public Bank.
PBLOF 5225 SMEBF 4197 1295 Q0F BSMAF IHHHF 1818

KLCI down 1.07% as key blue chips drag

23h theedgemarkets
KUALA LUMPUR (June 18): The FBM KLCI fell 1.07% at mid-morning today as regional markets spooked by the escalating US-China trade spat mostly retreated.
PBLOF 7251 5183 PECGF 7060 UPBMF 4065 5681 2291 1163 1295 2089 5014 KLKBY 2445 5347 3301 1996 TNABY 5819 MYPRY TNABF GEBHF

Bursa opens lower

2018-06-18 malaymail
KUALA LUMPUR, June 18 — Bursa Malaysia opened lower today, dragged down by cautious investor sentiment due to potential US-China trade war fears.
PBLOF 1295 BSMAF 1818

KLCI falls 1.13%, tracks regional markets spooked by trade wars

2018-06-18 theedgemarkets
KUALA LUMPUR (June 18): The FBM KLCI fell 1.13% in early trade this morning, tracking losses at most regional markets spooked by the U.S.-China trade wars.
PBLOF 4065 5681 1295 3034 KLKBY 2445 4588 3867 1996 6888 5819 AXXTF

Bursa stays lower at mid-morning

2018-06-14 malaymail
KUALA LUMPUR, June 14 — Bursa Malaysia remained lower at mid-morning today with continuous selling activities in selected heavyweights.
0133 PBLOF 5225 SNHHF 1295 Q0F BSMAF IHHHF 1818

Bursa slides at opening

2018-06-14 malaymail
KUALA LUMPUR, June 14 — Bursa Malaysia opened lower today in line with regional markets and weighed down by selling activities in heavyweights.
PBLOF 8789 1295 BSMAF 7123 1818 0020

KLCI falls 0.94% as plantations, blue chips drag

2018-06-14 theedgemarkets
KUALA LUMPUR (June 14): The FBM KLCI fell 0.94% in early trade this morning tracking losses at regional markets, dragged by key index-linked plantation stocks and blue chips.
PBLOF 4065 2291 1295 5014 6033 KLKBY 2445 PNADF 6888 5819 MYPRY AXXTF PNAGF

KLCI flat, ringgit weakens as investors await US interest rate decision

2018-06-13 theedgemarkets
KUALA LUMPUR (June 13): The FBM KLCI fell 0.59 point to close at 1,763.57 points while the ringgit depreciated to its weakest level against the US dollar today at 3.9992 as investors awaited the US Federal Reserve's interest rate decision later today.

Bursa Malaysia ends lower

2018-06-13 malaymail
KUALA LUMPUR, June 13 — Bursa Malaysia ended lower for the third consecutive day in line with most regional markets ahead of the US Federal Reserve’s policy decision later today, and also weighed down by selling in selected heavyweights.
PBLOF 5681 1295 BSMAF 7077 1818

Bursa cuts some losses at mid-afternoon

2018-06-13 malaymail
KUALA LUMPUR, June 13 — Bursa Malaysia pared down losses at mid-afternoon today, weighed down by selected heavyweights.
PBLOF 5225 8789 Q0F 1295 BSMAF 7077 IHHHF 1818

KLCI pares loss, down 0.25% as select blue chips drag

2018-06-13 theedgemarkets
KUALA LUMPUR (June 13): The FBM KLCI pared some of its loss at the midday break today and was down 0.25%, dragged by select blue chips.
PBLOF 7113 5253 BATS TPGVF 4162 AMMHF 1295 7153 2089 7077 5226 1201 PNAGF SPMXF UPBMF 7087 6033 TGLVY PNADF 4588 1015 SPMXY 5819 BSMAF 3719 1818

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

21h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...